Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would drugmakers agree to reduce their prices right away?

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.

Weight loss tops many folks’ list of New Years resolutions, and lots of people are turning to cutting-edge weight-loss drugs like Ozempic to help them drop excess pounds. These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs),

GLP-1 drugs spiked in popularity and price over the past few years, leaving the door open for illegal pharmacies to try and sell cheaper counterfeit versions.